Pfizer Lyme vaccine candidate heads to FDA

Ella Jeffries / beckershospitalreview - Pfizer and Valneva’s investigational Lyme disease vaccine candidate, PF-07307405 (LB6V), demonstrated more than 70% efficacy in preventing Lyme disease among individuals age 5 and older, according to topline phase 3 trial results. The prespecified analysi…

AI Summary: Pfizer is advancing a Lyme disease vaccine toward FDA submission despite a messy late‑stage picture: efficacy signals above 70% were reported while a pivotal trial missed its primary endpoint and struggled with low case numbers. Regulators must weigh public health need against statistical nuance as the company pushes for licensure.

#pharmaceuticals #publichealth #pfizer #biotech #drugdevelopment #fda #vaccinesafety #zoonoticdisease #infectiousdisease #clinicaltrials

Stopping tick spit: What a new saliva control map could mean for Lyme prevention

2 months / medicalxpress

Pfizer Lyme vaccine candidate heads to FDA

2 months / beckershospitalreview / Ella Jeffries

Lyme disease vaccine shows over 70% efficacy, but phase three misses main goal

2 months / medicalxpress

Pfizer's Lyme disease vaccine trial hampered by lack of cases

2 months / endpoints / Max Bayer

Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61

Pfizer Lyme vaccine candidate heads to FDA

Related Stories